The Lipitor Warning for GLP-1 Drugmakers
Pfizer’s Lipitor experience shows the structural risks that today’s GLP-1 innovators may soon face
-
By
-
Joe Renny
-
March 23, 2026
-
-
1
GLP-1 obesity drugs are compared to Lipitor, sharing similarities in commercial profiles and structural risks.
-
2
Lipitor's success in Norway was hindered by parallel imports, which accounted for 90% of the atorvastatin market during its patent period.
-
3
Norway's pharmacy market is dominated by three chains that prefer parallel imports for higher financial margins.
-
4
Price differentials within the European Economic Area create arbitrage opportunities, impacting pharmaceutical sales.
-
5
The legal framework in the EEA allows for the free movement of goods, complicating manufacturers' control over pricing.
